Results 291 to 300 of about 25,082 (343)

Frequency of hyperkalemia during optimization of guideline-directed medical therapy in ambulatory patients with HFrEF. [PDF]

Front Cardiovasc Med
Mendoza-Zavala GH, Reynoso-Hernandez G, Posada-Martinez EL, Sandoval-Jimenez M, Alejo-Arcos JIA, Rios-Felix K, Amaro-Balderas E, Gomez-Lopez M, Juarez-Comboni SC, Tejado-Gallegos LF, Joachin-Sanchez E, Olmos-Dominguez L, Aceves-Garcia M, Olalde-Roman MJ, Silva-Garcia MA, Almeida-Gutierrez E, Revilla-Monsalve C, Chavez-Mendoza A, Cigarroa-Lopez JA, Chávez-Iñiguez JS, Magaña-Serrano JA, Ivey-Miranda JB.   +21 more
europepmc   +1 more source

<i>ACE</i> inhibitors versus angiotensin receptor-neprilysin inhibitors for <i>HFrEF</i> management: A prospective cohort study from Indonesia. [PDF]

Narra J
Heriansyah T, Lestari ND, Hadi TF, Novia R, Munawarah I, Taufiqurrahman T, Yuvhendmindo SL, Bashori AA.   +7 more
europepmc   +1 more source

Inflammation-Driven Prognosis in Advanced Heart Failure: A Machine Learning-Based Risk Prediction Model for One-Year Mortality. [PDF]

J Inflamm Res
Zhou M, Du X.
europepmc   +1 more source

Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction. [PDF]

Cardiovasc Ther
Zhu X, Li X, Zhu L, Tong Z, Xu X.
europepmc   +1 more source

Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome. [PDF]

Front Med (Lausanne)
Rahman MM, Rahman A, Nishiyama A.
europepmc   +1 more source